Kadimastem Ltd.

Kadimastem Ltd. company information, Employees & Contact Information

Updated May 2026

Quick answer

Kadimastem Ltd. is a Biotechnology Research company and founded in 2009. It has approximately 30 employees on record. Contact data was last refreshed in May 2026. Find Kadimastem Ltd.'s verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Kadimastem Ltd. email format Kadimastem Ltd. management contacts

Related company profiles:

Kadimastem (TASE:KDST) A clinical stage biotech company introducing a cutting-edge TECHNOLOGY PLATFORM for the Development, Manufacturing, and Bio-Banking of functional human cells, providing OFF-THE-SHELF TREATMENT for multiple indications featuring ALS and Type 1 Diabetes as our top two leading projects.

Company Details

Employees
30
Founded
-
Address
Pinhas Sapir 7, Nes Ziona,israel 74140,israel
Phone
97297289100698
Email
in****@****tem.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
kadimastem.com
Keywords
stem cells, drug screening for myelin sheath, human oligodendrocytes, human beta cells, bio-banking, cell therapy, GMP facilities, cell production, type 1 diabetes, ALS, ALStreatment, DiabetesCURE, Clinicaltrials.
HQ
Nes Ziona, Israel
Competitors
AlloVir, Ascendis Pharma, uniQure, BiomX (NYSE: PHGE), Beam Therapeutics, NLS Pharmaceutics AG, Viking Therapeutics, Inc., Brainstorm Cell Therapeutics, Kalaris Therapeutics, Neurogene Inc..
Looking for a particular Kadimastem Ltd. employee's phone or email?

Kadimastem Ltd. Questions

News

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies - PR Newswire

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies PR Newswire

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 - Sahm

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 Sahm

NLS Pharma (NASDAQ: NLSP) and Kadimastem secure Nasdaq listing; NewcelX to trade as NCEL - Stock Titan

NLS Pharma (NASDAQ: NLSP) and Kadimastem secure Nasdaq listing; NewcelX to trade as NCEL Stock Titan

NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting - PR Newswire

NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting PR Newswire

84.4% Ownership Stake: Kadimastem-NLS Pharma Merger Creates NewCelX with ALS and Diabetes Pipeline - Stock Titan

84.4% Ownership Stake: Kadimastem-NLS Pharma Merger Creates NewCelX with ALS and Diabetes Pipeline Stock Titan

Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger - PR Newswire

Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger PR Newswire

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients - PR Newswire

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients PR Newswire

NLS Pharmaceutics Approve Merger with Kadimastem - citybiz

NLS Pharmaceutics Approve Merger with Kadimastem citybiz

Kadimastem and NLS Pharmaceutics Merger Update - citybiz

Kadimastem and NLS Pharmaceutics Merger Update citybiz

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy - PR Newswire

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy PR Newswire

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing - PR Newswire

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing PR Newswire

NLS Pharmaceutics Raises $3M at Premium for Game-Changing Merger: ALS and Diabetes Trials Next - Stock Titan

NLS Pharmaceutics Raises $3M at Premium for Game-Changing Merger: ALS and Diabetes Trials Next Stock Titan

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - Yahoo Finance

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement Yahoo Finance

NLS Pharmaceutics CEO Issues Letter to Shareholders - PR Newswire

NLS Pharmaceutics CEO Issues Letter to Shareholders PR Newswire

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - PR Newswire

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment PR Newswire

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics - PR Newswire

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics PR Newswire

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - PR Newswire

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger PR Newswire

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - PR Newswire

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies PR Newswire

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market S - PR Newswire

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market S PR Newswire

Strategic Biotech Merger: NLS Pharmaceutics and Kadimastem Unite to Transform Neurodegenerative Treatment - Stock Titan

Strategic Biotech Merger: NLS Pharmaceutics and Kadimastem Unite to Transform Neurodegenerative Treatment Stock Titan

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - ACCESS Newswire

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement ACCESS Newswire

Companies like Kadimastem Ltd.

Brainstorm Cell Therapeutics logo - Similar company to Kadimastem Ltd.

Brainstorm Cell Ther...

32
Ascendis Pharma logo - Similar company to Kadimastem Ltd.

Ascendis Pharma

1.19K
uniQure logo - Similar company to Kadimastem Ltd.

Uniqure

311
Beam Therapeutics logo - Similar company to Kadimastem Ltd.

Beam Therapeutics

557
Viking Therapeutics, Inc. logo - Similar company to Kadimastem Ltd.

Viking Therapeutics,...

43
AlloVir logo - Similar company to Kadimastem Ltd.

Allovir

17
NLS Pharmaceutics AG logo - Similar company to Kadimastem Ltd.

Nls Pharmaceutics Ag

6
Kalaris Therapeutics logo - Similar company to Kadimastem Ltd.

Kalaris Therapeutics

13
Neurogene Inc. logo - Similar company to Kadimastem Ltd.

Neurogene Inc.

107
BiomX (NYSE: PHGE) logo - Similar company to Kadimastem Ltd.

Biomx (Nyse: Phge)

64

Top Kadimastem Ltd. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant